Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26425416 | 0.90 | NFE2L2 (0.47) | NFE2L2RELAMAOAMAOBHTR2A | |
| SCHEMBL26426007 | 0.89 | PTGS1 (0.47) | CYP1A2NFE2L2 | |
| SCHEMBL26425434 | 0.89 | NFE2L2 (0.40) | CYP1A1CYP1A2CYP1B1PPARGALDH1A1 | |
| SCHEMBL26425420 | 0.89 | RELA (0.42) | CYP1A1CYP1A2CYP1B1PPARGALDH1A1 | |
| SCHEMBL26425426 | 0.89 | NFE2L2 (0.47) | NFE2L2LMNAMAOB | |
| SCHEMBL26425419 | 0.89 | NFE2L2 (0.42) | CYP1A2NFE2L2RELAMAOAMAOB | |
| SCHEMBL26426000 | 0.86 | PTGS1 (0.37) | ALDH1A1NFE2L2EPAS1 | |
| SCHEMBL26425412 | 0.86 | AHR (0.43) | PPARGALDH1A1NFE2L2EPAS1 | |
| SCHEMBL28960351 | 0.86 | PTGS1 (0.37) | ALDH1A1NFE2L2EPAS1 | |
| SCHEMBL30241117 | 0.86 | NQO2 (0.51) | CYP1A1CYP1A2CYP1B1TUBB1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | TP53, ANXA5, MCL1 | CYP1A1 4837/4885CYP1A2 4846/4885CYP1B1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.